Molecular Hydrogen as a Potential Adjunctive Therapy to Improve Renal Function and Reduce Fatigue in an Elderly Patient With Chronic Comorbidities: A Case Report
Lin YT, Lu JW, Ho YJ, Lui SW, Hsieh TY, Wang KY, Liu FC. · In vivo (Athens, Greece). 2025;39(1):572-576.
What kind of evidence is this?
Human
Case report
Cardiovascular and circulatory health
Other forms
Not reported in this record.
Not reported in this record.
Methods at a glance
Human participants studied for cardiovascular and circulatory health. See eligibility criteria in the linked full text.
Human study; the article does not state one consolidated sample total, so no total is inferred.
Multiple article-specific time points; see the linked full methods.
Full text reports an oral H₂-generating preparation. No numeric quantity is inferred beyond the source wording.
an oral H₂-generating preparation — H₂ only unless the full text explicitly reports oxygen co-delivery.
The full article describes the H₂ intervention but does not report a numeric H₂ concentration.
Not applicable — no inhaled H₂ intervention was identified in the full article.
No inhaled O₂ co-delivery was identified for this non-inhalation intervention.
Placebo or matched control reported in the full article.
Outcomes and reported result
clinical symptoms or functional scores, tumor growth or cancer markers, oxidative-stress and antioxidant markers, apoptosis or cell injury, histology or tissue damage, metabolic laboratory measures
Article-reported result excerpt (24 words maximum): “(D) Following the administration of molecular hydrogen capsule therapy, renal function improved, and the patient denied experiencing frequent lower limb edema..” This excerpt is not a complete result summary; consult the linked full text for all positive and null findings.
The complete machine-readable article was checked for source identity, methods, intervention quantities, results, tables, funding and conflict declarations. This public record is based on the full article.
A reported association, difference or mechanism is not automatically a clinical benefit. Null findings, outcome type, study design and precision all matter.
Cautions and applicability
Human evidence; design, sample size and comparator limit interpretation. No funding statement was identified in the machine-readable full article; absence is not inferred. No explicit conflict statement was identified in the machine-readable full article; absence is not inferred.
Applies only to the population and protocol reported in this cardiovascular and circulatory health article.
Not reported in this record.
Not reported in this record.
Not reported in this record.
No single-study GRADE certainty rating is assigned. Certainty is assessed by important outcome across a complete eligible evidence set, not by attaching a final grade to one source.
Sources and record status
PMID: 39740897 · DOI: 10.21873/invivo.13862
A free full article is available through PubMed Central.
Official Europe PMC JATS full article and PubMed/PMC identifiers; structured full-text extraction and validation completed 8 August 2026.
2026-08-10